LIMN
What one share of Liminatus Pharma holds
Biological Products, (No Diagnostic Substances)
Liminatus is a pre-clinical stage, single-asset biopharmaceutical company. Liminatus is developing novel cancer therapies that exploit the body’s immune system. The Company’s clinical candidate is a humanized anti CD47 monoclonal antibody.
Liminatus Pharma’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$0.36 |
|---|---|
| Cash and investments | $0.05 |
| Book value | $0.01 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2024 | — | −$0.20 | — | −$0.08 | — | −$1.11 |
| 2025 | — | −$0.43 | $0.00 | −$0.42 | — | −$0.36 |